Synsight
Synsight was a company created in 2013, by two co-founders PhD Computer aided drug design: Cyril Bauvais (CEO) and Guillaume Bollot (CSO). In july 2024, Synsight was acquired by @iktos, an AI drug discovery company. Its tech is based on AI drug design and cell imaging, including a proprietary cell based assay named MTBench, to profile compounds modulators of protein-protein and protein-RNA interactions, and protein agregation.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
1
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Synsight
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Synsight
1 distinct titles indexed · top 1 shown.
- 1r & d project manager
Sign up to unlock all 2 contacts at Synsight
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Synsight
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.